- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02392364
Variable Interval Versus Set Interval Aflibercept for DME (EVADE)
January 2, 2019 updated by: California Retina Consultants
Treat and Extend Versus Dosing Every Eight Weeks With Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema (EVADE Study)
The purpose of this study is to compare the safety and efficacy of intravitreal Eylea injections at a set interval, versus a variable dosing schedule (likely longer than one month), based on a specific individual's disease progression.
There will be approximately 50 men and women at least 18 years of age, diagnosed with type 1 or type 2 diabetes, taking part in this study at 5 locations in the United States.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Bakersfield, California, United States, 93039
- California Retina Consultants - Bakersfield
-
Santa Barbara, California, United States, 93103
- California Retina Consultants - Santa Barbara Office
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults 18 years and older with Type 1 or Type 2 diabetes mellitus
- Patients with diabetic macular edema involving the center of the macular in the study eye (CST must measure at least 350µm on Heidelberg SDOCT, or 333µm on Cirrus SDOCT)
- Decrease in vision determined to be primarily due to DME in the study eye
- BCVA ETDRS letter score 78 to 24 (20/32 to 20/320) in the study eye
- Willing and able to comply with clinical visits and study related procedures
- Willing and able to provide signed informed consent
Exclusion Criteria:
- History of vitreoretinal surgery in the study eye
- Laser photocoagulation (panretinal or macular) in the study eye within 90 days of baseline
- Previous use of intraocular or periocular corticosteroids in the study eye within 90 days of baseline
- History of intravitreal anti-VEGF treatments in the study within 90days prior to baseline (not including prior intravitreal aflibercept injection [see exclusion criteria #5])
- Any history of intravitreal aflibercept
- Active proliferative diabetic retinopathy (PDR) in the study eye
- History of idiopathic or autoimmune uveitis in the study eye
- Cataract surgery in the study eye within 90 days of baseline
- Aphakia in the study eye
- Yttrium aluminum garnet (YAG) capsulotomy in the study eye within 30 days of baseline
- Any intraocular surgery in the study eye within 90 days of day 1
- Vitreomacular traction or epiretinal membrane in the study eye that is thought to affect central vision
- Current iris neovascularization, vitreous hemorrhage, or traction retinal detachment in the study eye
- Pre-retinal fibrosis involving the macula in the study eye
- Uncontrolled glaucoma (defined as any patient who has had filtration surgery in the past, or likely to need filtration surgery in the future, or has IOP ≥30mmHg)
- Myopia of a spherical equivalent prior to any possible refractive or cataract surgery of ≥-8 diopters
- Concurrent disease in the study eye, other than DME, that could compromise BCVA, require medical or surgical intervention during the study period, or could confound interpretation of the results (including retinal vascular occlusion, retinal detachment, macular hole, or choroidal neovascularization of any cause)
- Ocular media of insufficient quality to obtain fundus and SDOCT images
- Current treatment for a systemic infection
- Administration of systemic anti-angiogenic agents within 180 days of baseline
- Uncontrolled diabetes mellitus, in the opinion of the investigator
- Uncontrolled blood pressure (define as systolic >180mmHg, or diastolic >110mmHg while patient is sitting)
- History of CVA or MI within 180 days of baseline
- Renal failure requiring dialysis or renal transplant
- Known serious allergy to fluorescein
- Participation in an investigational study within 30 days prior to baseline that involved treatment with any drug (excluding vitamins and minerals) or device
- Any women who are pregnant, breast-feeding, or attempting to become pregnant
- Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly) *Contraception is not required for men with documented vasectomy. **Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Variable Treatment Dosing Arm
Group 1 will receive injections every 4 weeks until diabetic macular edema on the OCT is decreased and stable.
At that point, the length of time between injections may increase, depending on how the study eye is doing.
The interval between study eye treatments may maintain, increase, or decrease once the variable treatment dosing has begun.
This will be determined by an algorithm designed into a computer program
|
|
Active Comparator: Monthly Treatment Arm
Group 2 will receive 5 intravitreal injections, monthly, for the first 5 months of the study.
After those initial injections, visits/treatment will be every 8 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
BCVA Change
Time Frame: Week 0 to Week 52
|
Change in mean BCVA from baseline to week 52
|
Week 0 to Week 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Dilsher S Dhoot, MD, California Retina Consultants
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 15, 2015
Primary Completion (Actual)
November 15, 2018
Study Completion (Actual)
November 15, 2018
Study Registration Dates
First Submitted
March 2, 2015
First Submitted That Met QC Criteria
March 18, 2015
First Posted (Estimate)
March 19, 2015
Study Record Updates
Last Update Posted (Actual)
January 3, 2019
Last Update Submitted That Met QC Criteria
January 2, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014-01-CRC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Macular Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
-
Centre Hospitalier Universitaire DijonRecruiting
-
Uptown Eye SpecialistsNot yet recruitingDiabetic Macular Edema
-
Hospices Civils de LyonRecruiting
-
Hoffmann-La RocheActive, not recruiting
Clinical Trials on Intravitreal Aflibercept Injection
-
Indonesia UniversityBayerCompletedDiabetic Retinopathy | Diabetic Macular Edema | Clinically Significant Macular EdemaIndonesia
-
Innovent Biologics (Suzhou) Co. Ltd.SuspendedDiabetic Macular Edema | Neovascular Age-related Macular DegenerationChina
-
Chengdu Kanghong Biotech Co., Ltd.TerminatedNeovascular Age-related Macular DegenerationUnited States, Argentina, Australia, Austria, Belgium, Canada, Chile, Colombia, Germany, Hong Kong, Lithuania, Mexico, Netherlands, New Zealand, Peru, Philippines, Poland, Portugal, Singapore, Spain, Switzerland, Taiwan
-
Chengdu Kanghong Biotech Co., Ltd.TerminatedNeovascular Age-related Macular DegenerationUnited States, Bulgaria, China, Czechia, Denmark, France, Hungary, Israel, Italy, Latvia, Slovakia, United Kingdom
-
M. Ali Khan, MDUniversity of California, Los Angeles; Southeastern Retina Associates; Eye Associates...RecruitingProliferative Vitreoretinopathy | Retinal Detachment With Multiple Breaks, Unspecified EyeUnited States
-
Kim's Eye HospitalBayerRecruitingRetinal Angiomatous ProliferationKorea, Republic of
-
Instituto de Olhos de GoianiaUnknownChoroidal Retinal NeovascularizationBrazil
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Regeneron PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationUnited States
-
Regeneron PharmaceuticalsBayerCompleted